Hideaki Tahara

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. ncbi Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  2. ncbi Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
  3. ncbi Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray
    Takako Suda
    Department of Surgery and Bioengineering, Institute of Medical Science, The University of Tokyo, 4 6 1, Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    Cancer Sci 97:411-9. 2006
  4. ncbi Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity
    Tetsuya Saito
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Cancer Sci 99:2028-36. 2008
  5. ncbi Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms
    Masahisa Jinushi
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108 8639, Japan
    J Exp Med 206:1317-26. 2009
  6. ncbi Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1
    Hidenobu Ishizaki
    Department of Surgery and Bioengineering, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
    Clin Cancer Res 12:5841-9. 2006
  7. ncbi Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12
    Teruo Kaiga
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 461 Shirokane dai, Minato ku, Tokyo 108 8639, Japan
    J Immunol 178:7571-80. 2007
  8. ncbi Suppression of choroidal neovascularization by vaccination with epitope peptide derived from human VEGF receptor 2 in an animal model
    Hidenori Takahashi
    Department of Ophthalmology, The Institute of Medical Science, School of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, Japan
    Invest Ophthalmol Vis Sci 49:2143-7. 2008
  9. ncbi Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target
    Takashi Shimokawa
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108 8639, Japan
    Int J Oncol 29:381-6. 2006
  10. ncbi Cancer gene therapy using in vivo electroporation of Flt3-ligand
    Kazuya Shimao
    Department of Surgery and Bioengineering Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Int J Oncol 27:457-63. 2005

Collaborators

Detail Information

Publications25

  1. ncbi Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  2. ncbi Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
    ..The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions...
  3. ncbi Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray
    Takako Suda
    Department of Surgery and Bioengineering, Institute of Medical Science, The University of Tokyo, 4 6 1, Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    Cancer Sci 97:411-9. 2006
    ..These results strongly suggest that SCRN1 is a novel TAA and these peptides, both native and modified, may be applicable for cancer vaccines to treat gastric cancer...
  4. ncbi Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity
    Tetsuya Saito
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Cancer Sci 99:2028-36. 2008
    ..These results may suggest that local expression of IL-18 combined with in vivo DC mobilization with Flt3L is clinically applicable as a new strategy of DC immunotherapy...
  5. ncbi Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms
    Masahisa Jinushi
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108 8639, Japan
    J Exp Med 206:1317-26. 2009
    ..Collectively, these findings suggest that systemic MFG-E8 blockade might intensify the antitumor activities of existing therapeutic regimens through coordinated cell-autonomous and immune-mediated mechanisms...
  6. ncbi Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1
    Hidenobu Ishizaki
    Department of Surgery and Bioengineering, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
    Clin Cancer Res 12:5841-9. 2006
    ..CONCLUSIONS: These results strongly suggest that VEGFR1 is a promising target for antiangiogenic cancer vaccine and warrants further clinical development of this strategy...
  7. ncbi Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12
    Teruo Kaiga
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 461 Shirokane dai, Minato ku, Tokyo 108 8639, Japan
    J Immunol 178:7571-80. 2007
    ....
  8. ncbi Suppression of choroidal neovascularization by vaccination with epitope peptide derived from human VEGF receptor 2 in an animal model
    Hidenori Takahashi
    Department of Ophthalmology, The Institute of Medical Science, School of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, Japan
    Invest Ophthalmol Vis Sci 49:2143-7. 2008
    ..The present study examined the efficacy of this immunotherapy against age-related macular degeneration (AMD) using a choroidal neovascularization (CNV) model...
  9. ncbi Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target
    Takashi Shimokawa
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108 8639, Japan
    Int J Oncol 29:381-6. 2006
    ..These findings suggest that TOMM34 is involved in the growth of cancer cells, and may contribute to the development of novel anticancer drugs and/or diagnosis for CRC...
  10. ncbi Cancer gene therapy using in vivo electroporation of Flt3-ligand
    Kazuya Shimao
    Department of Surgery and Bioengineering Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Int J Oncol 27:457-63. 2005
    ..These results suggest that Flt3L gene transfer using in vivo electroporation could mobilize DCs into tumor site. Additional means to induce maturation of these DCs could have a positive impact on anti-tumor effects of this strategy...
  11. ncbi Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas
    Takeshi Watanabe
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4 6 1, Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    Cancer Sci 96:498-506. 2005
    ..These findings have provided a novel insight into carcinogenesis of the stomach, colon and liver, and will be helpful for the development of novel therapeutic strategies to a wide range of human cancers...
  12. ncbi Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2
    Satoshi Wada
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Cancer Res 65:4939-46. 2005
    ..These results in vitro and in vivo strongly suggest that the epitope peptides derived from VEGFR2 could be used as the agents for antiangiogenic immunotherapy against cancer in clinical settings...
  13. ncbi [Translational research in gene therapy]
    Takuya Takayama
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo
    Nippon Rinsho 63:491-5. 2005
  14. ncbi [Genome analysis and cancer therapy]
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Japan
    Nippon Geka Gakkai Zasshi 106:706-9. 2005
    ..Furthermore, the finding of tumor associated antigens lead to the development of not only new diagnostic methods but also novel therapeutic modalities including cancer vaccine. Some of the successful efforts are referred and discussed...
  15. ncbi Cytokine gene-mediated immunotherapy: current status and future perspectives
    Masahisa Jinushi
    Department of Surgery and Bioengineering Advanced Clinical Research Center, Institute of Medical Sciences, University of Tokyo, Tokyo, Japan
    Cancer Sci 100:1389-96. 2009
    ..The principles operative in these vaccination strategies may prove applicable to other immunotherapy strategies, especially in combination with other therapeutic modalities, such as chemotherapy and targeted therapy...
  16. ncbi Ex vivo-expanded DCs induce donor-specific central and peripheral tolerance and prolong the acceptance of donor skin grafts
    Tomoyoshi Yamano
    Division of Immunobiology, Research Institute for Biological Sciences, Tokyo University of Science, Tokyo, Japan
    Blood 117:2640-8. 2011
    ..Tolerance induction by adoptive transfer of FLDCs could be a useful approach for promoting graft acceptance after organ transplantation...
  17. ncbi Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402
    Toshiyuki Baba
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokane dai, Minato city, Tokyo, 108 8639, Japan
    J Transl Med 8:84. 2010
    ..Since it is the most common HLA Class I allele in the Japanese population, we performed a phase I clinical trial of cancer vaccination using the HLA-A*2402 gp100 peptide to treat patients with metastatic melanoma...
  18. ncbi Early activation and interferon-γ production of tumor-infiltrating mature CD27 high natural killer cells
    Yoshihiro Hayakawa
    Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
    Cancer Sci 102:1967-71. 2011
    ..This work implicates the importance of IFN-γ as a positive regulatory factor for NK cell recruitment into the tumor microenvironment and an effective antitumor immune effector response...
  19. ncbi Ring finger protein 43 as a new target for cancer immunotherapy
    Naotaka Uchida
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    Clin Cancer Res 10:8577-86. 2004
    ..These results strongly suggest that RNF43 is a new TAA of colon cancer. Furthermore, these results also suggest that our strategy might be a promising one to efficiently discover clinically useful TAAs...
  20. ncbi Proatherogenic effect of interleukin-18 is exerted with high-fat diet, but not with normal diet in spontaneously hyperlipidemic mice
    Takatoshi Imai
    Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
    J Atheroscler Thromb 18:1090-101. 2011
    ..The purpose of this study was to reveal the effect of increased serum IL-18 within its physiological fluctuations on atherosclerosis development under different conditions of dietary fat content...
  21. ncbi Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case
    Yuichi Ando
    Department of Surgery and Bioengineering, Institute of Medical Science, University of Tokyo, 4-6-1 Minato-ku, Tokyo 108-8639, Japan
    Surg Today 35:157-60. 2005
    ..Our results are consistent with previous reports that show imatinib to be effective for the treatment of metastatic GIST, and also suggest that imatinib at 400 mg daily for more than 7 months is well tolerated in Japanese adults...
  22. ncbi A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms
    Taisei Mushiroda
    Laboratory for Pharmacogenetics, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN, Tokyo, Japan
    J Hum Genet 50:442-7. 2005
    ..Our results open the possibility that prediction of CNI-induced cardiovascular complications can lead to better prognosis and quality of life among kidney-transplant patients, and to improved immunosuppressive regimens...
  23. ncbi Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo
    Hiroyuki Mushiake
    Department of Surgery and Bioengineering, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokane-dai, Minato-ku, 108-8639, Tokyo, Japan
    Cancer Immunol Immunother 54:120-8. 2005
    ..We demonstrated that DCs might play an important role in chemotherapy, and the combination therapy of S-1 and LNT presents a promising chemoimmunotherapy, which might lead to better survival for cancer patients...
  24. ncbi MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy
    Mina Hikichi
    Core Facility for Therapeutic Vectors, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    Mol Ther 19:1107-15. 2011
    ..These results demonstrate that miRNA-based gene regulation is a potentially novel and versatile platform for engineering vaccinia viruses for cancer virotherapy...
  25. ncbi Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E(2)
    Marimo Sato
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639
    Cancer Sci 94:1091-8. 2003
    ....